E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

NCT05388877 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Financial issues

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Neoplasm in the Central Nervous System
Metastatic Melanoma

Interventions

DRUG: Dabrafenib
DRUG: MEK-1/MEKK-1 Inhibitor E6201
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging

Sponsor

Mayo Clinic